These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19920114)

  • 21. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
    Bradley DA; Daignault S; Ryan CJ; Dipaola RS; Cooney KA; Smith DC; Small E; Mathew P; Gross ME; Stein MN; Chen A; Pienta KJ; Escara-Wilke J; Doyle G; Al-Hawary M; Keller ET; Hussain M
    Invest New Drugs; 2011 Dec; 29(6):1432-40. PubMed ID: 20336348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
    Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
    Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
    Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
    J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
    Mayer EL; Baurain JF; Sparano J; Strauss L; Campone M; Fumoleau P; Rugo H; Awada A; Sy O; Llombart-Cussac A
    Clin Cancer Res; 2011 Nov; 17(21):6897-904. PubMed ID: 21903773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
    Danila DC; Morris MJ; de Bono JS; Ryan CJ; Denmeade SR; Smith MR; Taplin ME; Bubley GJ; Kheoh T; Haqq C; Molina A; Anand A; Koscuiszka M; Larson SM; Schwartz LH; Fleisher M; Scher HI
    J Clin Oncol; 2010 Mar; 28(9):1496-501. PubMed ID: 20159814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
    Takahashi S; Miyazaki M; Okamoto I; Ito Y; Ueda K; Seriu T; Nakagawa K; Hatake K
    Cancer Sci; 2011 Nov; 102(11):2058-64. PubMed ID: 21781226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
    Lee RJ; Saylor PJ; Michaelson MD; Rothenberg SM; Smas ME; Miyamoto DT; Gurski CA; Xie W; Maheswaran S; Haber DA; Goldin JG; Smith MR
    Clin Cancer Res; 2013 Jun; 19(11):3088-94. PubMed ID: 23553848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene signature-guided dasatinib therapy in metastatic breast cancer.
    Pusztai L; Moulder S; Altan M; Kwiatkowski D; Valero V; Ueno NT; Esteva FJ; Avritscher R; Qi Y; Strauss L; Hortobagyi GN; Hatzis C; Symmans WF
    Clin Cancer Res; 2014 Oct; 20(20):5265-71. PubMed ID: 25172932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
    Johnson ML; Riely GJ; Rizvi NA; Azzoli CG; Kris MG; Sima CS; Ginsberg MS; Pao W; Miller VA
    J Thorac Oncol; 2011 Jun; 6(6):1128-31. PubMed ID: 21623279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
    Dayyani F; Varkaris A; Araujo JC; Song JH; Chatterji T; Trudel GC; Logothetis CJ; Gallick GE
    Prostate; 2013 Jun; 73(9):979-85. PubMed ID: 23371521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
    Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
    BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
    Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
    Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
    Johnson FM; Bekele BN; Feng L; Wistuba I; Tang XM; Tran HT; Erasmus JJ; Hwang LL; Takebe N; Blumenschein GR; Lippman SM; Stewart DJ
    J Clin Oncol; 2010 Oct; 28(30):4609-15. PubMed ID: 20855820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
    Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
    J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
    Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
    J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
    Wang XD; Reeves K; Luo FR; Xu LA; Lee F; Clark E; Huang F
    Genome Biol; 2007; 8(11):R255. PubMed ID: 18047674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
    Chi KN; Ellard SL; Hotte SJ; Czaykowski P; Moore M; Ruether JD; Schell AJ; Taylor S; Hansen C; Gauthier I; Walsh W; Seymour L
    Ann Oncol; 2008 Apr; 19(4):746-51. PubMed ID: 18056648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
    Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
    J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.